2. Academic Validation
  3. PRMT3 and CARM1: Emerging Epigenetic Targets in Cancer

PRMT3 and CARM1: Emerging Epigenetic Targets in Cancer

  • J Cell Mol Med. 2025 Feb;29(4):e70386. doi: 10.1111/jcmm.70386.
Jiezuo Huang 1,  Beining Qiao 1,  Yixin Yuan 2,  Yuxuan Xie 3,  Xiaomeng Xia 4,  Fenghe Li 4,  Lei Wang 5
Affiliations

Affiliations

  • 1 College of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
  • 2 Xiangya College of Public Health, Central South University, Changsha, China.
  • 3 Hunan Normal University School of Medicine, Changsha, China.
  • 4 Department of Gynaecology and Obstetrics, Second Xiangya Hospital, Central South University, Changsha, China.
  • 5 NHC Key Laboratory of Carcinogenesis and the Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China.
PMID: 39964832 DOI: 10.1111/jcmm.70386
Abstract

The family of protein arginine methyltransferases (PRMTs) occupies an important position in biology, especially during the initiation and development of Cancer. PRMT3 and CARM1(also known as PRMT4), being type I protein arginine methyltransferases, are key in controlling tumour progression by catalysing the mono-methylation and asymmetric di-methylation of both histone and non-histone substrates. This paper reviews the functions and potential therapeutic target value of PRMT3 and CARM1 in a variety of cancers. Studies have identified abnormal expressions of PRMT3 and CARM1 in several malignancies, closely linked to Cancer progression, advancement, and resistance to treatment. Such as hepatocellular carcinoma, colorectal Cancer, ovarian Cancer, and endometrial Cancer. These findings offer new strategies and directions for Cancer treatment, especially in enhancing the effectiveness of conventional treatment methods.

Keywords

CARM1; PRMT3; cancer; epigenetic; inhibitor.

Figures